#United States #Palo Alto #pancreatic cancer #Sonire Therapeutics #HIFU therapy

Sonire Therapeutics Initiates Pioneering U.S. Clinical Trial of HIFU Therapy for Pancreatic Cancer

Sonire Therapeutics, a cutting-edge clinical-stage medical device company based in the United States, has recently made headlines with the commencement of its inaugural clinical trial in the U.S., labeled the SUNRISE-II trial. This vital study aims to evaluate the efficacy of a proprietary High-Intensity Focused Ultrasound (HIFU) therapy system in treating patients diagnosed with pancreatic cancer, one of the most challenging and deadly forms of the disease.

The SUNRISE-II trial coordinates a sophisticated methodology to assess both the safety and feasibility of utilizing ultrasound-guided HIFU technology specifically tailored for patients suffering from pancreatic cancer. This study marks a significant milestone for Sonire as it enters the U.S. clinical and regulatory landscape. Building on its previous development experiences in Japan, Sonire is progressing towards an innovative therapeutic approach that could enhance treatment options for pancreatic cancer, which is regarded as one of the leading contributors to cancer-related fatalities in the United States.

Tohru Satoh, the President and CEO of Sonire Therapeutics, articulated the significance of this initiative by stating, "Treatment options for pancreatic cancer remain extremely limited due to the complexity and location of the disease. Initiating SUNRISE-II in the United States is a defining milestone for our company. It enables us to begin building clinical evidence in a new market while advancing a treatment approach designed to be less invasive and more accessible for patients."

In March 2026, the first patient underwent treatment using the HIFU system, performed by Pejman Ghanouni, MD, PhD, at Stanford Medicine, who is also the principal investigator for the SUNRISE-II clinical trial. This progress revives hope for proactive and effective treatment pathways for pancreatic cancer patients.

According to reports from the American Cancer Society, the five-year survival rate for pancreatic cancer stands at only approximately 13%, significantly lower than that of numerous other major cancers. Sonire's innovative HIFU therapy system integrates real-time ultrasound guidance, facilitating precise and minimally invasive tumor ablation. This methodology permits healthcare professionals to closely monitor the treatment process while delivering targeted energy directly to the tumor site without the necessity of general anesthesia.

The potential benefits of this therapy extend beyond mere precision; it also seeks to alleviate the procedural burdens typically placed on patients and healthcare providers. Additionally, by optimizing treatment delivery in outpatient settings, Sonire hopes to democratize access to these advanced therapeutic options.

The SUNRISE-II trial epitomizes Sonire's broader vision to solidify its foothold in the U.S. clinical development arena, aiming to establish high-quality evidence that supports forthcoming regulatory submissions and global commercialization efforts. By engaging with prominent healthcare institutions, the company is poising itself to facilitate the swift adoption of a groundbreaking, less intrusive treatment modality targeted at patients who grapple with tough-to-treat tumors.

For those interested in further information regarding the SUNRISE-II clinical trial, additional details can be accessed through the ClinicalTrials.gov website: ClinicalTrials.gov SUNRISE-II.

About Sonire Therapeutics

Founded in February 2020 in Tokyo and now operating from Palo Alto, California, Sonire Therapeutics Inc. is dedicated to transforming oncological treatments through innovative acoustic engineering. The company is pioneering sonic-driven technologies aimed specifically at delivering non-invasive and effective solutions for solid tumors, starting with pancreatic cancer. The commitment to patient-centered outcomes positions Sonire at the forefront of next-generation medical solutions. For further insights into their groundbreaking work, please visit Sonire Therapeutics.